ACTA1 and pulmonary arterial hypertension: MiR‐223‐3p attenuated the progression of PAH by suppressing proliferation and decreasing α‐SMA expression in PASMCs, a key cell type constituting the vascular wall of small pulmonary arteries and contributing to pulmonary vascular remodelling.36 To ensure that our preclinical findings are consistent with future clinical studies, according to the latest guidelines of optimal methods and more stringent study in PAH36 and key principles and guidelines for reporting preclinical research delivered by the National Institutes of Health,37 both in vitro and in vivo experiments are important.